Last reviewed · How we verify

NCT03151525: SCILLA

Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis

Status unknown Phase 4 Last updated 12 May 2017
What this trial tests

Phase 4 trial testing Azathioprine in Colitis, Ulcerative in 100 participants. Status unknown.

Timeline
8 May 2017
Primary endpoint
3 October 2019
3 April 2020

Quick facts

Lead sponsorIstituto Clinico Humanitas
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date8 May 2017
Primary completion3 October 2019
Estimated completion3 April 2020
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituto Clinico Humanitas

Who can join

Adults 18 to 65, any sex, with Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ulcerative colitis patients treated with Infliximab (IFX) in deep remission after at least 12 months of treatment will be randomized to continue IFX or to stop IFX and start Azathioprine (AZA). Each patient will be followed for 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Azathioprine

Trials testing the same drug.

Other recruiting trials for Colitis, Ulcerative

Currently open trials in the same condition.

Other Istituto Clinico Humanitas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03151525.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing